‘Requip XR’ would extend GSK’s patent term: Analyst

May 20 2005

Analysts predict top annual revenue for GlaxoSmithKline’s Requip could hit $500 million, quite a change for a drug that delivers ...

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.